Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 in EGFR/HER2-mutant Non-Small Cell Lung Cancer and Other Solid Tumors
jRCT2080224915Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (9 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-788, Pharmacokinetics of TAK-788 and 1 more. Started Oct 2019; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224915.